Remeditex Ventures
VC Fund
Dallas, United States
Remeditex Ventures is a VC fund in Dallas focused on Health Care and Biotechnology. Remeditex was formed to invest in high quality, innovative, early stage projects that are judged to have commercialization potential. The goal is to help investigators establish the commercial viability of their research making it attractive to traditional investors.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Remeditex Ventures invests in
Health CareBiotechnologyTherapeuticsMedical DevicePharmaceutical
Stages Remeditex Ventures invests in
Series BSeries CSeries ASeries D
Countries Remeditex Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dennis Keith Stone
|
|||
John Creecy
|
|||
|
Brett Ringle
|
|||
Claire Aldridge
|
|||
|
John Elwood
|
Investment Focus
Industry
- Health Care 7 (50%)
- Biotechnology 6 (43%)
- Therapeutics 5 (36%)
- Medical Device 4 (29%)
- Pharmaceutical 3 (21%)
Stage
- Series B 4 (29%)
- Series C 4 (29%)
- Series A 2 (14%)
- Series D 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dennis Keith Stone
CSO
|
CSO | Total investments: 3 | Find email | |
|
John Creecy
Chief Executive Officer & Director
|
Chief Executive Officer & Director | Total investments: 7 | Find email | |
|
Brett Ringle
President
|
President | Total investments: 0 | Find email | |
|
Claire Aldridge
Vice President, Venture Development
|
Vice President, Venture Development | Total investments: 0 | Find email | |
|
John Elwood
Vice President, Business Development
|
Vice President, Business Development | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rodin Therapeutics
|
Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biologycapabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC). | $27M / Series C / Sep 18, 2017 | |
VYNE Therapeutics
|
VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chroniccough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20. | $50.5M / Series C / Jul 18, 2017 | |
Peloton Therapeutics
|
A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a uniquecombination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs. | $52.4M / Series D / Sep 15, 2016 | |
Navitor Pharmaceuticals
|
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTORpathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases.It was founded in 2009 and headquartered in Cambridge, Massachusetts. | $33M / Series B / Dec 18, 2015 | |
Viridian Therapeutics
|
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets andindications. | $40.7M / Series C / Nov 10, 2015 | |
|
Viridian Therapeutics
|
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets andindications. | $8.5M / Series B / Feb 18, 2015 | |
|
Viridian Therapeutics
|
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets andindications. | $7M / Series B / Jun 27, 2014 | |
Bellicum Pharmaceuticals
|
Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factorsthat can influence the potency and duration of this response. | $14.7M / Series B / Jan 07, 2014 | |
Bi02 Medical
|
BiO2 Medical offers Angel Catheter that provides prophylactic Pulmonary Embolism protection and access to the central venous system. It was formerly known as Artificial Airways. Bi02 Medical design, develops, and manufactures medical devices. It develops Angel Catheter, a catheter-based IVC filter for the prevention of pulmonary embolism incritical care patients worldwide. The Angel Catheter allows for insertion and access to the central venous system for administering medications, fluids, or blood products; blood sampling; and monitoring of central venous pressure. The company was founded in 2006 and is based in San Antonio, Texas with a research and development, and manufacturing facility in Golden, Colorado. | $12M / Series C / Sep 07, 2012 | |
|
Viridian Therapeutics
|
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets andindications. | $20M / Series B / Apr 24, 2012 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical Device VC Funds
9,894 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Remeditex Ventures invest in?
Remeditex Ventures invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Remeditex Ventures?
Public channels for Remeditex Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Remeditex Ventures?
The team at Remeditex Ventures includes Dennis Keith Stone (CSO), John Creecy (Chief Executive Officer & Director) and Brett Ringle (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
